Invivyd, Inc. (Nasdaq: IVVD) announced its financial results for the third quarter ended September 30, 2026, alongside updates regarding its clinical development programs and corporate leadership. The company reported a net loss of $33.5 million for the quarter, compared to a loss of $10.5 million in the prior year period.

Commercial performance for the company’s lead product, PEMGARDA (pemivibart), showed growth despite a challenging market environment. Q3 2026 net product revenue was $15.4 million, representing an 18% increase compared to $13.1 million in Q3 2025. This growth was driven by increased patient demand. However, the company noted that the U.S. FDA has issued a twelve-month advanced notice of the termination of PEMGARDA’s Emergency Use Authorization (EUA), with the termination set to take effect in mid-2027.

On the clinical front, Invivyd highlighted results from the LIBERTY Phase 3 trial of VYD2311 (ibramvibart). The trial demonstrated that VYD2311 has superior safety and tolerability compared to an mRNA-based COVID-19 vaccine. Additionally, the data showed that VYD2311 combined with an mRNA vaccine did not interfere with vaccine-induced neutralizing titers and instead added to them.

The company also provided an update on the DECLARATION Phase 3 program, which is intended to support a Biologics License Application (BLA) for VYD2311 under the Accelerated Approval Program. Invivyd stated that the timing for the declaration of Phase 3 data has been updated as a result of ongoing dialogue with the FDA regarding the accelerated regulatory approach. The company plans to conduct a prespecified interim analysis imminently.

Invivyd announced the initiation of the FLINTLOCK Phase 2 trial, which will evaluate VYD2311 in adults aged 18 to 65 with Long COVID or Post-Vaccination Syndrome. Furthermore, the company presented preclinical data for VMS063, a monoclonal antibody candidate for measles, at IDWeek 2026.

Corporate leadership changes included the appointment of Marc W. Elia, the company’s Chairman, as Chief Executive Officer. In addition, Ajay Royan was appointed Lead Independent Director, and Ian Sheffield was appointed as an independent director.

As of September 30, 2026, Invivyd reported cash and cash equivalents of $126.4 million. Research and development expenses for the quarter were $18.7 million, while selling, general and administrative expenses were $30.3 million.